When a nerve impulse arrives at a 5-HT or noradrenaline nerve terminal the neurotransmitter is released from the synaptic vesicle into the synaptic cleft. Neurotransmitter molecules bind to their specific receptors on the post-synaptic membrane and the nerve impulse is propagated or inhibited, depending on the receptor type. 5-HT and noradrenaline molecules are then released from their receptors and taken back into the nerve terminal via either the 5-HT or noradrenaline re-uptake transporters. 5-HT and noradrenaline are degraded by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT), these enzymes are found in the nerve terminal.1,2
Click here: Learn about the normal processes of serotonin and noradrenaline synaptic activity
Related content
Advances in blood biomarkers are transforming the diagnosis and prognosis of Alzheimer’s disease, helping to assess pathology, disease progression, and co-existing pathologies.
Overview of how blood-based biomarkers may support screening, diagnosis, staging, prognosis, and treatment decisions across the Alzheimer’s disease continuum.
Overview of a plasma biomarker testing pathway for symptomatic Alzheimer’s disease, using p-tau217 and eMTBR-tau243 to guide diagnostic assessment and identify underlying pathology.